-
1
-
-
78649888517
-
Lipoprotein(a) as a cardiovascular risk factor: current status
-
Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.
-
(2010)
Eur Heart J
, vol.31
, pp. 2844-2853
-
-
Nordestgaard, B.G.1
Chapman, M.J.2
Ray, K.3
Boren, J.4
Andreotti, F.5
Watts, G.F.6
-
3
-
-
45849151730
-
Role of lipoprotein(a) in cardiovascular disease current and future perspectives
-
Berglund L, Anuurad E. Role of lipoprotein(a) in cardiovascular disease current and future perspectives. J Am Coll Cardiol 2008;52:132-4.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 132-134
-
-
Berglund, L.1
Anuurad, E.2
-
4
-
-
0031729386
-
Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies
-
Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-6.
-
(1998)
Clin Chem
, vol.44
, pp. 2301-2306
-
-
Craig, W.Y.1
Neveux, L.M.2
Palomaki, G.E.3
Cleveland, M.M.4
Haddow, J.E.5
-
5
-
-
0034609562
-
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies
-
Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
-
(2000)
Circulation
, vol.102
, pp. 1082-1085
-
-
Danesh, J.1
Collins, R.2
Peto, R.3
-
6
-
-
41549133097
-
Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data
-
Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008;168:598-608.
-
(2008)
Arch Intern Med
, vol.168
, pp. 598-608
-
-
Bennet, A.1
Di Angelantonio, E.2
Erqou, S.3
Eiriksdottir, G.4
Sigurdsson, G.5
Woodward, M.6
-
7
-
-
67651210632
-
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
-
Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
-
(2009)
JAMA
, vol.302
, pp. 412-423
-
-
Erqou, S.1
Kaptoge, S.2
Perry, P.L.3
Di, A.E.4
Thompson, A.5
White, I.R.6
-
8
-
-
73549097512
-
Genetic variants associated with Lp(a) lipoprotein level and coronary disease
-
Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28.
-
(2009)
N Engl J Med
, vol.361
, pp. 2518-2528
-
-
Clarke, R.1
Peden, J.F.2
Hopewell, J.C.3
Kyriakou, T.4
Goel, A.5
Heath, S.C.6
-
9
-
-
67049167090
-
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction
-
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9.
-
(2009)
JAMA
, vol.301
, pp. 2331-2339
-
-
Kamstrup, P.R.1
Tybjaerg-Hansen, A.2
Steffensen, R.3
Nordestgaard, B.G.4
-
10
-
-
0027987849
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
-
(1994)
Lancet
, vol.344
, pp. 1383-1389
-
-
-
11
-
-
0033751381
-
Mechanism of action of niacin on lipoprotein metabolism
-
Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2000;2:36-46.
-
(2000)
Curr Atheroscler Rep
, vol.2
, pp. 36-46
-
-
Kamanna, V.S.1
Kashyap, M.L.2
-
12
-
-
77952397461
-
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
-
Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-61.
-
(2010)
Atherosclerosis
, vol.210
, pp. 353-361
-
-
Bruckert, E.1
Labreuche, J.2
Amarenco, P.3
-
13
-
-
44149123549
-
Recommendations for the use of LDL apheresis
-
Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-55.
-
(2008)
Atherosclerosis
, vol.198
, pp. 247-255
-
-
Thompson, G.R.1
-
14
-
-
61549101898
-
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
-
Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-39.
-
(2009)
Nat Clin Pract Cardiovasc Med
, vol.6
, pp. 229-239
-
-
Jaeger, B.R.1
Richter, Y.2
Nagel, D.3
Heigl, F.4
Vogt, A.5
Roeseler, E.6
-
15
-
-
0028954425
-
Events per person year - a dubious concept
-
Windeler J, Lange S. Events per person year - a dubious concept. BMJ 1995;310:454-6.
-
(1995)
BMJ
, vol.310
, pp. 454-456
-
-
Windeler, J.1
Lange, S.2
-
16
-
-
76249103587
-
Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care
-
Stefanutti C, Vivenzio A, Di Giacomo S, Mazzarella B, Ferraro PM, Abbolito S. Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfus Apher Sci 2009;42:21-6.
-
(2009)
Transfus Apher Sci
, vol.42
, pp. 21-26
-
-
Stefanutti, C.1
Vivenzio, A.2
Di Giacomo, S.3
Mazzarella, B.4
Ferraro, P.M.5
Abbolito, S.6
-
17
-
-
84871623944
-
-
Committee on Ethical and Scientific Issues Studying the Safety of Approved Drugs (Faden RR, co-chair, Goodman SN, co-chair). Ethical and scientific issues isn studying the safety of approved drugs; report brief May 2012. Available at: Accessed on 20 October 2012
-
Committee on Ethical and Scientific Issues Studying the Safety of Approved Drugs (Faden RR, co-chair, Goodman SN, co-chair). Ethical and scientific issues isn studying the safety of approved drugs; report brief May 2012. Available at: http://www.iom.edu/Reports/2012/Ethical-and-Scientific-Issues-in-Studying-the-Safety-of-Approved-Drugs.aspx. Accessed on 20 October 2012.
-
-
-
-
18
-
-
0016264378
-
Judgment under uncertainty: heuristics and biases
-
Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science 1974;185:1124-31.
-
(1974)
Science
, vol.185
, pp. 1124-1131
-
-
Tversky, A.1
Kahneman, D.2
-
19
-
-
0034706254
-
For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial
-
Weijer C, Shapiro SH, Cranley GK. For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. BMJ 2000;321:756-8.
-
(2000)
BMJ
, vol.321
, pp. 756-758
-
-
Weijer, C.1
Shapiro, S.H.2
Cranley, G.K.3
-
20
-
-
36348975228
-
Effects of torcetrapib in patients at high risk for coronary events
-
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
-
(2007)
N Engl J Med
, vol.357
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
Grundy, S.M.4
Kastelein, J.J.5
Komajda, M.6
-
21
-
-
84863652218
-
Rate vs rhythm control in atrial fibrillation: can observational data trump randomized trial results?
-
Dewland TA, Marcus GM. Rate vs rhythm control in atrial fibrillation: can observational data trump randomized trial results?Arch Intern Med 2012;172:983-4.
-
(2012)
Arch Intern Med
, vol.172
, pp. 983-984
-
-
Dewland, T.A.1
Marcus, G.M.2
-
22
-
-
84864841084
-
The importance of potential studies that have not existed and registration of observational data sets
-
Ioannidis JP. The importance of potential studies that have not existed and registration of observational data sets. JAMA 2012;308:575-6.
-
(2012)
JAMA
, vol.308
, pp. 575-576
-
-
Ioannidis, J.P.1
|